Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

77 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with recurrent platinum-resistant ovarian cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a global, multi-center, randomized, double-blind, controlled phase 3 study in patients with newly diagnosed, stage III or IV non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (collectively referred to as ovarian cancer).

The purpose of this study is to confirm the recommended phase II dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The proposed clinical trial is designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine as a first-line treatment for naïve subjects with stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg three times a day and 300 mg three times a day, clinical treatment duration of four weeks, to determine the maximum dose of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine. The extended phase II part of the study will focus on the efficacy of antroquinonol with standard treatment.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study compares radiographic progression free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib plus enzalutamide versus enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

The main purpose of this study is to compare the overall response rate (ORR) and overall survival (OS) of NKTR-214 combined with nivolumab to that of a tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.